Figure 3
From: LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor
LRIG1 expression in breast cancers. (A) Box plot of the LRIG1 gene signature in the UNC337 human breast tumour data set based on intrinsic subtypes. LRIG1 expression appears to be significantly upregulated only in the Luminal A intrinsic subtype compared with normal (P=5.83e–40). (B) When divided into high (50/128) and low (29/128) LRIG1-expression groups, patients with high LRIG1 expression exhibit longer relapse-free survival. P-values reflect statistical significance of analysis of variances (ANOVAs; P=0.00561).
